Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Are we seeing any breakthroughs in the treatment of AML?

Wolfgang Hiddemann, MD, PhD, from Ludwig-Maximilians University, Munich, Germany, talks to us about the current state of treating acute myeloid leukemia (AML), in which current treatment regimens may potentially cure 40% of younger AML patients but there are presently no breakthroughs in the treatment of older AML patients. Prof. Hiddemann explains that apart from midostaurin, currently researched novel drugs and biomarkers have not been observed to have any significant effectiveness and clinical benefit in AML patients. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.